Back

Combined pharmacotherapy in atrial fibrillation patients and their risk of stroke, dementia, and cardiovascular deaths

25 August 2023 (09:15 - 09:50)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention: epidemiology (2) Epidemiology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Mozhu Ding

Karolinska Institute, Stockholm (Sweden)

6 More presentations in this session

Presentation thumbnail
Early screening for metabolic syndrome opens a window of opportunity - learnings from a long-term, population-based study.
Mrs L. Loennberg (Vasteras, SE)
Abstract Slides Video
Presentation thumbnail
Aspirin overuse in primary prevention: nationwide temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in adults with and without diabetes
Doctor A. Kristensen (Frederiksberg, DK)
Abstract Slides Video
Presentation thumbnail
Sex specific lifetime risk of incident cardiovascular events. Results from a large British population-based cohort study.
Doctor T. Pana (Aberdeen, GB)
Abstract Slides Video
Presentation thumbnail
Influence of birth weight on later life cardiovascular structure, function and disease: unpacking influences from direct genetic effects versus intrauterine programming
Mr A. Morley (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Genetic risk, modifiable risk factors, and atrial fibrillation in the Danish diet, cancer, and health cohort
Ms T. Frederiksen (Aarhus, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention: epidemiology (2)

The Event

Event poster

ESC Congress 2023

25 August 2023 09:15 CET
You may be interested in
thumbnail
Congress Session
Registries, observational, and other studies on atrial fibrillation
thumbnail
Congress Session
Registries on atrial fibrillation and sudden death
thumbnail
Congress Presentation
Change in incidence of ischemic stroke and mortality among patients with atrial fibrillation over a period of 30 years, a nationwide, register-based cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources